Navigation Links
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Date:10/21/2007

Japan, Plavix(R) is the only widely approved antiplatelet agent used in monotherapy for prevention of atherothrombotic events in patients with recent myocardial infarction (hear attack), recent ischaemic stroke or established peripheral arterial disease, and in combination with acetylsalicylic acid for the treatment of patients with acute coronary syndrome (unstable angina or NSTEMI) including those who are to be managed medically and those managed with PCI (with or without stent) and for STEMI patients.

Plavix(R) is one of the most studied cardiovascular medications available to patients with short and long term clinical benefit, and after a decade of prescriptions, it remains the oral antiplatelet therapy with the broadest range of indications worldwide.

About Plavix(R)

Plavix(R), also marketed as Iscover(R), is an antiplatelet agent which prevents platelets from sticking together and forming clots in the arteries. Plavix(R) was first authorized in the United States in 1997 and the European Union in 1998 and has been prescribed to more than 70 millions patients worldwide.

In Japan, in addition to the new approval for acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is planned, Plavix(R) is also approved for "reduction of recurrence after ischemic cerebrovascular disorder (excluding cardiogenic cerebral embolism)" one of the 3 major causes of death in Japan.

The efficacy and safety profile of Plavix(R) have been established through landmark clinical trials including more than 100,000 patients worldwide. Outside Japan, Plavix(R) has shown favourable tolerability profile as compared to ASA and an acceptable increase in major bleedings when used in combination with ASA (no statistical difference when only PCIs are considered).

In Japan, Plavix(R) is marketed by sanofi-aventis K.K. Plavix(R) is marketed in more than 100 countries by sanofi-a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
2. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9pthtm/home_healthcare ... Healthcare Global Market - Forecast to 2020" report ... is expected to reach more than $300+ billion growing ... home healthcare equipment market is expected to grow at ... Home healthcare is gaining a tremendous attention over hospitals ...
(Date:5/5/2015)... May 5, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... of $4.0 million for the three months ended March ... loss of $22.6 million for the same period in ... higher revenue from milestone payments earned from its partners ... GAAP basis, Isis reported a loss from operations of ...
(Date:5/5/2015)... Big Market Research presents a detailed analysis ... , ( France , Germany ... UK) and Japan . Current scientific views on ... the 5-year test volume and sales forecasts by country for HAV ... Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in ...
Breaking Medicine Technology:Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 132015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
... WASHINGTON, April 5, 2011 The American Center for Law ... sweeping victory for pro-life pharmacy owners in Illinois after a ... today issued a decision striking down a state law that ... of emergency contraception, even if doing so violates their religious ...
... April 5, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... that the Company intends to release its first quarter 2011 ... open of the U.S. financial markets.  The Company will also ... Time on April 27, 2011 to discuss its financial results ...
Cached Medicine Technology:ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle 2ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle 3Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings 2
(Date:5/5/2015)... 06, 2015 Social Media Regulatory Affairs ... Media Your Most Powerful Marketing Tool and Get the ... http://www.fdanews.com/SocialMedia , Social media … Is it ... media’s reach. Patients are using it — learning about ... what they’ve discovered. , But, it can become a ...
(Date:5/5/2015)... 2015 The Journal of ... “ Priority interventions to improve the management of ... research of the ACCORD program ” , As ... actors, including clinicians, patients and family members, managers, ... which included knowledge gap, “work in silos”, lack ...
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... Doylestown, PA (PRWEB) May 05, 2015 The ... , raised $110,000 to benefit their global research, outreach and ... and silent auction, and awards ceremony that attracted hundreds of ... anniversary of the discovery of the hepatitis B virus (HBV) ... Dr. Blumberg received the Nobel Prize in Medicine for his ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... FRIDAY, Oct. 29 (HealthDay News) -- More than half ... ill patients want to have full control over life-support ... doctors, finds a new study. It included 230 ... mechanical ventilation who had about a 50 percent chance ...
... 28, 2010) -- Scientists at Weill Cornell Medical College have ... viruses, two lethal and emerging viruses for which there is ... lead to new therapies for measles, mumps and the flu. ... journal Public Library of Science (PLoS) Pathogens . The ...
... Strong immunity may play a key role in determining long ... fertility, a Princeton University study has concluded. An 11-year ... remote island off the coast of Scotland that gauged the ... some people get sicker than others when exposed to the ...
... have identified a mechanism controlling the function of a ... may function to prevent abnormal tumor growth. When the ... a phosphate, it no longer binds DNA, changing the ... a new diagnostic marker (phosphorylated TCF3) that may be ...
... , THURSDAY, Oct. 28 (HealthDay News) Early humans were ... ago in Africa, more than 50,000 years earlier than previously ... that modern behavior developed over time during the Middle Stone ... Europe, as some scientists have thought. Researchers from the ...
... Developing a molecular fingerprint for head and neck cancer ... and often-times disfiguring form of cancer, according to researchers at ... taken the first step toward doing that by identifying five ... genes, tumor grade, and vascular invasion and location of the ...
Cached Medicine News:Health News:Most Health Proxies Would Make End-of-Life Decisions Themselves: Study 2Health News:Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers 2Health News:Wild Scottish sheep could help explain differences in immunity 2Health News:Wild Scottish sheep could help explain differences in immunity 3Health News:Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer 2Health News:Early Humans More Advanced Than Thought 2Health News:Study identifies 5 risk factors for late-stage head and neck cancer 2Health News:Study identifies 5 risk factors for late-stage head and neck cancer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: